Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides
- PMID: 8967957
Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides
Abstract
Normal hematopoietic progenitors and acute myelogenous leukemia cells show a differential requirement for the encoded product of c-myb proto-oncogene for proliferation. To determine whether c-myb is also differentially required for the proliferation of hematopoietic progenitors of chronic myelogenous leukemia (CML), mononuclear cells derived from both chronic phase and blast crisis were exposed to c-myb antisense oligodeoxynucleotides and assayed for colony-forming ability. Exposure of CML-BC cells from 12 patients to c-myb antisense oligodeoxynucleotides resulted in significant (p<001) inhibition of leukemia colony formation (average inhibition 63%) and was accompanied by down-regulation of c-myb expression. Colonies derived from CML chronic phase progenitors were virtually unaffected in 10 cases, but down-regulation of c-myb expression was not detected. However, in studies conducted with CD34+ leukemia cells, a subset highly enriched for hematopoietic progenitors, colony formation was inhibited at both disease stages, whereas CFU-GM colony formation derived from normal CD34+ cells was not affected by exposure to c-myb antisense oligodeoxynucleotides. These data suggest that CML chronic phase and blast crisis progenitors are both sensitive to the inhibitory effects of c-myb antisense oligomers, and that the lack of inhibition in partially purified CML-chronic phase progenitors is probably due to inefficient penetration of oligodeoxynucleotides into the clonogenic cells. The preferential effect of c-myb antisense oligodeoxynucleotides on colonies arising from the compartment that includes CML-CD34+ progenitors likely reflects the expansion of a cell population with high proliferative potential and elevated c-myb mRNA levels.
Similar articles
-
Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.Blood. 1992 Apr 15;79(8):1956-61. Blood. 1992. PMID: 1562723
-
Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.Leuk Lymphoma. 1993;11 Suppl 1:131-7. doi: 10.3109/10428199309047876. Leuk Lymphoma. 1993. PMID: 7504543
-
c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers.Leukemia. 1992 Jan;6(1):1-7. Leukemia. 1992. PMID: 1736009
-
Antisense oligodeoxynucleotides as therapeutic agents for chronic myelogenous leukemia.Antisense Res Dev. 1995 Spring;5(1):67-9. doi: 10.1089/ard.1995.5.67. Antisense Res Dev. 1995. PMID: 7613074 Review. No abstract available.
-
The effect of interferon-alpha on beta-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia.Leuk Lymphoma. 1998 Jan;28(3-4):241-54. doi: 10.3109/10428199809092680. Leuk Lymphoma. 1998. PMID: 9517496 Review.
Cited by
-
Autografting as first line treatment for chronic myeloid leukaemia.J Clin Pathol. 1998 Feb;51(2):92-5. doi: 10.1136/jcp.51.2.92. J Clin Pathol. 1998. PMID: 9602679 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Research Materials